Lv4
540 积分 2023-07-28 加入
Structure-driven design and precision translation of functionally diverse isatin-based CDK2 inhibitors: Advances in SAR, polypharmacology, and biomarker-guided cancer therapy
1个月前
已完结
Spotlight on 17‐AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
1个月前
已完结
The targeted protein degradation landscape
1个月前
已完结
Development and Optimization of a Scalable Enzymatic Cascade-Carbamate Formation Telescope Process for the Synthesis of CDK2 Selective Candidate Tegtociclib (PF-07104091)
2个月前
已完结
Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
An overview of CDK3 in cancer: clinical significance and pharmacological implications
3个月前
已完结
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
4个月前
已完结
Ozanimod, a functional sphingosine-1-phosphate receptor 1 antagonist, restores brainstem descending pain pathways in murine models of neuropathic pain
4个月前
已完结
Dissociation between the anti-allodynic effects of fingolimod (FTY720) and desensitization of S1P1 receptor-mediated G-protein activation in a mouse model of sciatic nerve injury
4个月前
已完结
皖公网安备34019202002308
